Loading company…
TearExo develops tear-based tests to detect cancer, including breast cancer.
TearExo develops a medical device that collects tears on Schirmer test paper for laboratory analysis, with the aim of detecting cancer, particularly breast cancer. The company describes its approach as supporting screening alongside ultrasound examinations. Based in Kobe, Japan, it was founded in 2022 by Ryo Horikawa, Eri Takano, Akiko Ichikawa, and Toshifumi Takeuchi. In August 2023, it raised JPY 50 million in seed funding led by Kobe University Capital, Chugin Capital Partners, Future Venture Capital, Japan Startup Support Association, and Leave a Nest Capital.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in